We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
Read MoreHide Full Article
GlaxoSmithKline plc (GSK - Free Report) announced data from a study, showing that patients whose asthma was uncontrolled with Xolair witnessed improved asthma control on switching to Glaxo’s new respiratory medicine, Nucala.
The OSMO study evaluated if severe asthma patients, whose disease was uncontrolled despite taking Novartis (NVS - Free Report) /Roche’s (RHHBY - Free Report) asthma medicine Xolair for an average of 2.5 years, saw better asthma control following a switch to Nucala. Data presented from the study showed that following the Nucala switch, these eligible patients experienced fewer symptoms, better lung function, improved asthma-related quality of life and fewer exacerbations. The data, which contributes to the extensive body of evidence for Nucala, were presented by Glaxo at American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in Orlando.
Nucala, approved to treat severe eosinophilic asthma, is one of the key new products in Glaxo’s respiratory portfolio, which is driving the top line.
In a separate press release, Glaxo and partner Pfizer, Inc.’s (PFE - Free Report) HIV-focused company, ViiV Healthcare, announced 24-week, interim data from the phase IIIb INSPIRING study, evaluating the safety and efficacy of investigational candidate dolutegravir in antiretroviral treatment-naive (ART-naïve) adults with HIV, co-infected with tuberculosis (TB).
Data from the study showed that 81% of HIV/TB co-infected adults (on a rifampin-based TB treatment), who were administered dolutegravir (50mg twice-daily) in combination with two nucleoside reverse transcriptase inhibitors (NRTI) therapies, maintained viral suppression. In the group of patients who received efavirenz (600mg once-daily) with two NRTIs, 89% maintained viral suppression. The data were presented at the annual conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
According to the company’s press release, tuberculosis accounts for around one in three AIDS-related deaths. There are many complications related to concurrent treatment of TB and HIV. The INSPIRING data supports the use of dolutegravir in HIV/TB co-infected patients.
Glaxo’s shares have risen 3.7% this year so far, outperforming the 1.7% decrease witnessed by the industry.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
GlaxoSmithKline plc (GSK - Free Report) announced data from a study, showing that patients whose asthma was uncontrolled with Xolair witnessed improved asthma control on switching to Glaxo’s new respiratory medicine, Nucala.
The OSMO study evaluated if severe asthma patients, whose disease was uncontrolled despite taking Novartis (NVS - Free Report) /Roche’s (RHHBY - Free Report) asthma medicine Xolair for an average of 2.5 years, saw better asthma control following a switch to Nucala. Data presented from the study showed that following the Nucala switch, these eligible patients experienced fewer symptoms, better lung function, improved asthma-related quality of life and fewer exacerbations. The data, which contributes to the extensive body of evidence for Nucala, were presented by Glaxo at American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in Orlando.
Nucala, approved to treat severe eosinophilic asthma, is one of the key new products in Glaxo’s respiratory portfolio, which is driving the top line.
In a separate press release, Glaxo and partner Pfizer, Inc.’s (PFE - Free Report) HIV-focused company, ViiV Healthcare, announced 24-week, interim data from the phase IIIb INSPIRING study, evaluating the safety and efficacy of investigational candidate dolutegravir in antiretroviral treatment-naive (ART-naïve) adults with HIV, co-infected with tuberculosis (TB).
Data from the study showed that 81% of HIV/TB co-infected adults (on a rifampin-based TB treatment), who were administered dolutegravir (50mg twice-daily) in combination with two nucleoside reverse transcriptase inhibitors (NRTI) therapies, maintained viral suppression. In the group of patients who received efavirenz (600mg once-daily) with two NRTIs, 89% maintained viral suppression. The data were presented at the annual conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
According to the company’s press release, tuberculosis accounts for around one in three AIDS-related deaths. There are many complications related to concurrent treatment of TB and HIV. The INSPIRING data supports the use of dolutegravir in HIV/TB co-infected patients.
Glaxo’s shares have risen 3.7% this year so far, outperforming the 1.7% decrease witnessed by the industry.
Glaxo has a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>